TG Therapeutics Inc
TGTX
Market Cap$5.72B
Close$
$-27.53
175.3% downside
Current Fair Value
175.3% downsideOvervalued by 175.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.72 Billion |
|---|---|
| Enterprise Value | $5.61 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.16 |
| Beta | 1.94 |
| Outstanding Shares | 146,677,783 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 134.95 |
|---|---|
| PEG | -91.64 |
| Price to Sales | 18.28 |
| Price to Book Ratio | 36.56 |
| Enterprise Value to Revenue | 14.53 |
| Enterprise Value to EBIT | 85.7 |
| Enterprise Value to Net Income | 143 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About TG Therapeutics Inc
CEO: Michael Weiss